Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(2.61) per share which missed the analyst consensus estimate of $(2.10) by 24.29 percent. This is a 8.75 percent decrease over losses of $(2.40) per share from the same period last year.
Related Posts
Mattel Announces Collaboration Between Masters Of The Universe And Paramount’s Teenage Mutant Ninja Turtles
The Two Heritage Brands Partner to Create New Toy Line, Turtles of Grayskull, Available in 2024Mattel, Inc. (NASDAQ:MAT) announced today the collaboration between its celebrated brand, Masters of the Universe and the
Elon Musk’s Potential Purchase Of House From Tesla Director Raises Governance Concerns: Report
The eight-member committee was formed to decide on the company's relocation from Delaware to Texas, a move initially proposed by Musk after a court rejected his $56 billion pay package.